Apellis Pharmaceuticals Inc [APLS] stock is trading at $30.37, up 5.52%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The APLS shares have gain 3.05% over the last week, with a monthly amount drifted -9.23%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Apellis Pharmaceuticals Inc [NASDAQ: APLS] stock has seen the most recent analyst activity on December 17, 2024, when Goldman downgraded its rating to a Neutral but kept the price target unchanged to $36 for it. Previously, Morgan Stanley started tracking the stock with Equal-Weight rating on November 21, 2024, and set its price target to $31. On October 25, 2024, RBC Capital Mkts initiated with a Sector Perform rating and assigned a price target of $25 on the stock. William Blair started tracking the stock assigning a Outperform rating. Scotiabank initiated its recommendation with a Sector Outperform. Piper Sandler started tracking with a Neutral rating for this stock on May 31, 2024, and assigned it a price target of $46. In a note dated February 05, 2024, Jefferies upgraded an Buy rating on this stock and boosted its target price from $68 to $80.
Apellis Pharmaceuticals Inc [APLS] stock has fluctuated between $24.34 and $71.90 over the past year. Currently, Wall Street analysts expect the stock to reach $70.8 within the next 12 months. Apellis Pharmaceuticals Inc [NASDAQ: APLS] shares were valued at $30.37 at the most recent close of the market. An investor can expect a potential return of 133.12% based on the average APLS price forecast.
Analyzing the APLS fundamentals
Apellis Pharmaceuticals Inc [NASDAQ:APLS] reported sales of 715.22M for the trailing twelve months, which represents a growth of 78.29%. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -0.31%, Pretax Profit Margin comes in at -0.35%, and Net Profit Margin reading is -0.35%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -1.04 and Total Capital is -0.31. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.98.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 29.43 points at the first support level, and at 28.50 for the second support level. However, for the 1st resistance point, the stock is sitting at 30.95, and for the 2nd resistance point, it is at 31.54.
Ratios To Look Out For
For context, Apellis Pharmaceuticals Inc’s Current Ratio is 4.36. Also, the Quick Ratio is 3.73, while the Cash Ratio stands at 2.07. Considering the valuation of this stock, the price to sales ratio is 5.28, the price to book ratio is 15.63.
Transactions by insiders
Recent insider trading involved Watson David O., General Counsel, that happened on Jan 29 ’25 when 695.0 shares were sold. Chief Commercial Officer, Townsend Adam J. completed a deal on Jan 29 ’25 to sell 695.0 shares. Meanwhile, Chief Financial Officer Sullivan Timothy Eugene sold 546.0 shares on Jan 29 ’25.
